Human Mouse (Species predicted to react based on 100% sequence homology)
Immunogen
A synthetic peptide corresponding to the center region of the Human FOXK1
Preparation
Produced in rabbits immunized with a synthetic peptide corresponding to the center region of the Human FOXK1, and purified by antigen affinity chromatography.
Source
Polyclonal Rabbit IgG
Purification
Protein A & Antigen Affinity
Formulation
PBS, pH7.0 with 0.03% Proclin300
Conjugate
Unconjugated
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Avoid repeated freeze-thaw cycles.
Immunochemical staining of human FOXK1 in human colon carcinoma with rabbit polyclonal antibody at 1:300 dilution, formalin-fixed paraffin embedded sections.
Immunochemical staining of human FOXK1 in human colon carcinoma with rabbit polyclonal antibody at 1:300 dilution, formalin-fixed paraffin embedded sections.
Forkhead-box (FOX) family transcription factors are implicated in carcinogenesis and embryogenesis. Transcriptional factor FOXK1 is a member of the FOX family, involved in the cell growth and metabolism. The higher expression of FOXK1 leads to a variety of diseases and may play an important role in the development of various tumors. The co-expression of FOXK1 and FHL2 enhances cell proliferation and metastasis through the induction of EMT. FOXK1 may be a potential therapeutic target for human prostate cancer. FOXK1 may act as an oncogene in human HCC, and knockdown of FOXK1 significantly inhibited HCC cell proliferation, migration and invasion, partly through the inactivation of Wnt/beta-catenin signaling pathway. That FOXK1 may be a novel therapeutic target to treat HCC. FOXK1 plays a key function in the ovarian cancer, it promotes cell proliferation and metastasis. FOXK1 serves as a novel molecular therapeutic target in ovarian cancer.